Literature DB >> 30263970

Meta-analysis of PET/CT Detect Lymph Nodes Metastases of Cervical Cancer.

Jianjiang Ruan1, Yueqiao Zhang2, Hong Ren2.   

Abstract

OBJECTIVE: The aim of this study was to assess the diagnostic value of PET/CT for metastatic lymph nodes in cervical cancer patients.
METHODS: Searching in the databases including PubMed, Embase, Web of Science, Cochrane Library and Google Scholar about non-invasive modalities for detecting lymph nodes metastases during 2000~2017. Following further screening, the extracted effective data were calculated by Meta-Disc 1.4 software, such as sensitivity (SEN), specificity (SPE), positive likelihood (LR+), and negative likelihood ratio (LR-).
RESULTS: we obtained 27 articles. The pooled estimates for sensitivity of PET/CT were 0.72 (95% CI, [0.69, 0.75]); for specificity were 0.96 (95% CI, [0.96, 0.97]). Its weighted AUC was 0.93.
CONCLUSION: PET/CT remains to be an effective method for diagnosis of metastatic lymph nodes from cervical cancer.

Entities:  

Keywords:  Cervical cancer; Lymph nodes metastases; Meta-analysis; PET/CT

Year:  2018        PMID: 30263970      PMCID: PMC6153451          DOI: 10.1515/med-2018-0065

Source DB:  PubMed          Journal:  Open Med (Wars)


Introduction

Cervical cancer is the second most common cancer in women all over the world. According to the statistics of the International Agency for Research on Cancer (IARC), the vast majority of new cases of cervical cancer worldwide each year are still in developing countries [1]. Because the survival rates of patients with lymph node metastasis are significantly lower than those without lymph node metastasis [2], an accurate detection of lymph node metastasis of cervical cancer is essential to ensure a proper treatment planning and prognosis for cervical cancer patients [3]. During the development of new radiotracers, the accuracy of Positron-emission tomography (PET) imaging has improved, particularly for antibody-targeted imaging. The oncologists have paid an attention to the field of diagnosis of metastatic lymph nodes by using PET. The principle of PET imaging is that the radioisotopes and other positron-specific radionuclide-labeled basic metabolic substrate accumulate in the lesion, detecting these particular radiation to determine metabolism of lesions. The F18-deoxyglucose is a common radio-labeled drug, which has the characteristics of small radiation, decay fast. F18-deoxyglucose may be injected into a patient, taken up preferentially by abnormal oncologic tissue, and measured using a PET scanner [4]. PET/CT with the advantages of molecular imaging techniques, anatomical and functional characteristics and confirmed diagnostic value in all kinds of solid tumors, PET/CT has been applied in the initial stages of cervical cancer patients, treatment planning, testing and follow-up after treatment and prognostic judgement [5]. In order to objectively evaluate a diagnostic value of PET/CT on lymph node metastasis of cervical cancer, we analyzed the quality of PET/CT in the diagnosis of cervical lymph node metastasis by using systematic review method.

Methods

Searching method

We conducted a search of PubMed, Embase, Web of Science, Cochrane Library and Google Scholar databases that were published between 2000 and 2017. We limited the search to study published in English. The medical subject heading terms and keywords used included “lymph node”, “PET/CT”, “sensitivity”, “specificity”, “accuracy”, and “diagnostic value”. Duplicate articles and unpublished studies from international meetings were excluded. The flow diagram of the retrieval process is shown in Figure 1.
Figure 1

The study selection process

The study selection process

Inclusion criteria

Studies were selected carefully on the basis of following criteria: The pathology results as “gold standard”, lymph nodes metastases were confirmed by surgery or biopsy; the diagnostic criteria were clear; a case control study (there are 2×2 contingency tables); direct or indirect access to true positive, false positive, false negative, true negative, sensitivity, specificity.

Excluding standard

Non-clinical controlled trials; lack of confirmed evidence by pathological examination; Incomplete data; Case reports; Review literature; Data published repeatedly.

Data extraction

Two authors independently assessed each literature, and then downloaded and extracted all the data by using standardized data-abstraction forms. The data extracted included year of publication, true positive, false positive, false negative, true negative, sensitivity, and specificity. For each study, 2×2 contingency tables were constructed. We calculated the sensitivity, specificity, and likelihood ratio (LR).

Statistical analysis

The sensitivity, specificity and 95% confidence interval (CI) of the literature were analyzed by Meta-disc 1.4 software, and the summary receiver operating characteristic (SROC) curves and forest map were drawn. According to the results of heterogeneity test, the corresponding fixed effect model or the random effect model is selected to quantify the effect values.

Results

Literature search and characteristics of eligible study

According to search strategy, 27 full articles were finally considered eligible for the review after evaluation. Figure 1 shows the flow diagram of study selection process. The detailed characteristics for the 27 eligible studies are summarized in Table 1.
Table 1

Baseline characteristics of included studies

StudiesComparisonsSampleMetastatic positionsTPFPFNTNSENSPE
Loft 2007(6)R27Pelvic311227595.7
Choi 2006(7)P22Pelvic, Para-aortic1034571.462.5
Choi 2006(7)R154Pelvic, Para-aortic1991411257.692.6
Chung 2007(8)P52Pelvic28431790.381.0
Chung 2010(9)P83Pelvic89204628.683.6
Chung 2009(2)P34Pelvic71101641.294.1
Crivellaro 2012(10)P69Pelvic42115226.796.3
Havrilesky 2003(11)P29Para-aortic12221385.786.7
Kim 2009(12)R553Pelvic, Para-aortic26303346444.193.9
Kim 2009(12)P79Pelvic, Para-aortic1414163546.771.4
Kitajima 2009(13)R1976Pelvic, Para-aortic23422192751.199.8
Kitajima 2009(13)P45Pelvic, Para-aortic6363050.090.9
Kitajima 2012(14)R200Pelvic, Para-aortic1462215838.996.3
Kitajima 2012(14)P32Pelvic12211792.389.5
Leblanc 2011(15)R132Para-aortic98621782.453.8
Lin 2003(16)P50Pelvic, Para-aortic12223485.794.4
Lv 2014(17)P87Pelvic, Para-aortic34704610086.8
Lv 2014(17)R1163Pelvic, Para-aortic6117610799198.4
Ma 2003(18)P104Pelvic, Para-aortic380066100100
Narayan 2001(19)P24Pelvic, Para-aortic10121183.391.7
Narayan 2001(19)R24Pelvic, Para-aortic4131657.194.1
Nogami 2014(20)R70Pelvic, Para-aortic54105133.392.7
Nogami 2014(20)R848Pelvic, Para-aortic1192580330.698.9
Park 2005(21)P36Pelvic6802210073.3
Park 2005(21)R72Pelvic91305010079.4
Reinhardt 2001(22)P35Pelvic10102410096
Reinhardt 2001(22)R292Pelvic174226989.598.5
Roh 2005(23)R72Pelvic90135040.9100
Roh 2005(23)P36Pelvic6082242.9100
Rose 1999(24)P16Para-aortic11005100100
Ryu 2003(25)P249Para-aortic2852316690.376.1
Sandvik 2011(26)P36Pelvic1342820.090.3
Signorelli 2011(27)P159Pelvic127941996.967.9
Sironi 2006(28)P48Pelvic, Para-aortic11513191.786.1
Sironi 2006(28)R1081Pelvic1335106072.299.7
Stecco 2016(29)P27Pelvic7311687.584.2
Stecco 2016(29)R216Pelvic26171116270.390.5
Belhocine 2002(30)P217Pelvic, Para-aortic193818770.498.4
Yeh 2002(31)P42Pelvic10212990.993.5
Yildirim 2008(32)R16Pelvic2221050.083.3
Baseline characteristics of included studies

Quality assessment

We assessed the quality of included studies according to QUADAS. Each study was respectively evaluated by two independent investigators. On average, the investigators disagreed on 3 of 11 items (range, 0–6). All disagreements were resolved by consensus.

The diagnostic sensitivity and specificity of PET/CT

The pooled diagnostic sensitivity and specificity of PET/CT are 0.72 (95% CI, [0.69, 0.75]), 0.96 (95% CI, [0.96, 0.97]), respectively. Significant heterogeneity was found among these studies (I2=88.6% and 93.0%). Due to significant heterogeneity of the data, we used a random effects model (Figure 2 and 3).
Figure 2

The plot for the sensitivity of PET/CT

Figure 3

The plot for the specificity of PET/CT

The plot for the sensitivity of PET/CT The plot for the specificity of PET/CT

The negative LR, positive LR and SROC curve of PET/CT

The pooled negative LR and positive LR of PET/CT are 0.34 (95% CI, [0.27, 0.44]), 9.12 (95% CI, [6.19, 13.45]), respectively (Figure 4 and 5). We successfully plotted the SROC curve. The area under the SROC curve (AUC) is 0.93 and the Q* is 0.86 (Figure 6).
Figure 4

The plot for the negative LR of PET/CT

Figure 5

The plot for the positive LR of PET/CT

Figure 6

The SROC curve of PET/CT

The plot for the negative LR of PET/CT The plot for the positive LR of PET/CT The SROC curve of PET/CT

Subgroup analysis

Subgroup analysis showed that the performance of PET/CT in detecting the lymph nodes metastases in patient-based unit, the pooled diagnostic sensitivity and specificity are 0.80 (95% CI, [0.76, 0.83]), 0.87 (95% CI, [0.84, 0.89]), respectively. In region-based unit, the pooled diagnostic sensitivity and specificity are 0.64 (95% CI, [0.60, 0.68]), 0.98 (95% CI, [0.98, 0.98]), respectively. Meta-analysis results are shown in Table 2.
Table 2

Subgroup analysis of pooled sensitivity, specificity, likelihood ratio

SubgroupSEN (95%CI)SPE (95%CI)+LR (95%CI)-LR (95%CI)
Analysis units
Patient-based (n=24)0.80(0.76-0.83)0.87(0.84-0.89)5.62(3.84–8.22)0.24(0.15-0.39)
Region-specific (n=16)0.64(0.60-0.68)0.98(0.98-0.98)15.60(7.73-31.48)0.43(0.33-0.56)
Metastatic positions
Pelvic (n=19)0.76(0.71-0.80)0.96(0.95-0.97)8.36(4.92–14.18)0.31(0.20–0.48)
Para-aortic (n=4)0.85(0.79-0.90)0.76(0.70-0.81)3.33(1.85-5.98)0.18(0.08-0.42)
Pelvic and Para-aortic (n=17)0.65(0.60-0.69)0.98(0.97-0.98)12.03(6.20-23.37)0.40(0.29-0.55)
Subgroup analysis of pooled sensitivity, specificity, likelihood ratio

Discussion

Cervical cancer is the third most common malignant tumor in women worldwide after breast cancer and colorectal cancer. With younger onset age, the increase of its incidence and recurrence rate after treatment, cervical cancer becomes significantly more influential on women’s health. Thus, a diagnosis of lymph node metastasis as early as possible has an important clinical significance. This systematic review included 27 studies of PET/CT for the diagnosis of cervical lymph node metastasis with surgical pathology as a reference standard. The data showed that the diagnosis of cervical lymph node metastasis with moderate sensitivity and specificity can be used as one of the effective diagnostic methods of cervical lymph node metastasis. To reduce heterogeneity, we performed a subgroup analysis. The result of subgroup analysis showed that the patient-based analysis unit had a higher sensitivity than the lymph node analysis unit, suggesting that cervical lymph node metastasis of suspected cases can be effectively screened when PET/CT diagnosis is positive. The lymph node as the unit of analysis compared with the patient as the unit of analysis has a higher specificity, likelihood ratio, the negative likelihood ratio, indicating that it can effectively rule out cases of cervical lymph node metastasis when the PET/CT diagnosis is negative. The quality of results evaluated in this systematic review proved to be insubstantial. Due to the low quality research and literature included being based mostly on the retrospective studies, there may be inherent choice bias. There was a large heterogeneity in this study. The combined analysis showed that I2 was more than 50%, the reason may be due to inconsistencies in criteria of interpretation of PET/CT. In the process of literature filtering we found: (1) most of the research in measuring results without using the blind method. Possible interpretation bias; (2) most of the literature does not report the sensitivity and specificity; these problems will inevitably affect the quality of the literature and combined analysis. In summary, PET/CT in the diagnosis of pelvic lymph node metastasis in cervical cancer ability has a moderate sensitivity and high specificity. The results will help us to accurately evaluate the preoperative cervical cancer patients.
  32 in total

1.  Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.

Authors:  Sang-Young Ryu; Moon-Hong Kim; Suck-Chul Choi; Chang-Woon Choi; Kyung-Hee Lee
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

2.  Contribution of whole-body 18FDG PET imaging in the management of cervical cancer.

Authors:  Tarik Belhocine; Alain Thille; Viviana Fridman; Adelin Albert; Laurence Seidel; Philippe Nickers; Frederic Kridelka; Pierre Rigo
Journal:  Gynecol Oncol       Date:  2002-10       Impact factor: 5.482

3.  18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.

Authors:  Cinzia Crivellaro; Mauro Signorelli; Luca Guerra; Elena De Ponti; Alessandro Buda; Carlotta Dolci; Cecilia Pirovano; Sergio Todde; Robert Fruscio; Cristina Messa
Journal:  Gynecol Oncol       Date:  2012-07-06       Impact factor: 5.482

4.  A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment.

Authors:  K Narayan; R J Hicks; T Jobling; D Bernshaw; A F McKenzie
Journal:  Int J Gynecol Cancer       Date:  2001 Jul-Aug       Impact factor: 3.437

5.  PET/CT evaluation of cervical cancer: spectrum of disease.

Authors:  Hongju Son; Arpakorn Kositwattanarerk; Monica P Hayes; Linus Chuang; Jamal Rahaman; Sherif Heiba; Josef Machac; Konstantin Zakashansky; Lale Kostakoglu
Journal:  Radiographics       Date:  2010-09       Impact factor: 5.333

6.  Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?

Authors:  Mauro Signorelli; Luca Guerra; Luca Montanelli; Cinzia Crivellaro; Alessandro Buda; Tiziana Dell'Anna; Maria Picchio; Rodolfo Milani; Robert Fruscio; Cristina Messa
Journal:  Gynecol Oncol       Date:  2011-08-19       Impact factor: 5.482

7.  Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings.

Authors:  Lian-Shung Yeh; Yao-Ching Hung; Yeh-You Shen; Chia-Hung Kao; Cheng-Chieh Lin; Cheng-Chun Lee
Journal:  Oncol Rep       Date:  2002 Nov-Dec       Impact factor: 3.906

8.  Comparison of DWI and PET/CT in evaluation of lymph node metastasis in uterine cancer.

Authors:  Kazuhiro Kitajima; Erena Yamasaki; Yasushi Kaji; Koji Murakami; Kazuro Sugimura
Journal:  World J Radiol       Date:  2012-05-28

9.  Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2009-01-29       Impact factor: 5.315

10.  Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings.

Authors:  Wu C Lin; Yao C Hung; Lian S Yeh; Chia H Kao; Ruoh F Yen; Yeh Y Shen
Journal:  Gynecol Oncol       Date:  2003-04       Impact factor: 5.482

View more
  3 in total

Review 1.  Implications of the new FIGO staging and the role of imaging in cervical cancer.

Authors:  Aki Kido; Yuji Nakamoto
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

2.  Comparison of positron emission tomography with computed tomography examination with histopathological assessment of pelvic lymph nodes in patients with cervical cancer treated surgically.

Authors:  Kamila Kaźmierczak; Witold Cholewiński; Błażej Nowakowski
Journal:  Contemp Oncol (Pozn)       Date:  2021-09-20

3.  Robotic Staging of Cervical Cancer With Simultaneous Detection of Primary Pelvic and Secondary Para-Aortic Sentinel Lymph Nodes: Reproducibility in a First Case Series.

Authors:  Philippe Van Trappen; Eveline De Cuypere; Nele Claes; Sarah Roels
Journal:  Front Surg       Date:  2022-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.